Close Menu

G551D

Based on promising results from a late-stage trial, Vertex Pharmaceuticals is hoping to expand the indication of its cystic fibrosis drug Kalydeco (ivacaftor) in other genetically defined patient populations.

European Commission Approves Vertex's Personalized CF Drug Kalydeco

FDA Grants Standard Review for Pfizer's NDA for Bosutinib in Ph-Positive CML

After data from a Phase III trial yielded significant improvements in the lung function of study participants who received the investigational drug VX-770, Vertex said it would work with regulatory agencies in the US and abroad to speed the drug's approval.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.